New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease
Go back to New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 64.63 -1.9 (2.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.53 | 52 Week High | $108.96 | |||
| Open | $65.24 | 52 Week Low | $62.12 | |||
| Day High | $66.26 | P/E | N/A | |||
| Day Low | $64.01 | EPS | $-1.27 | |||
| Volume | 1,457,634 | |||||
